AzTrials
AzTrials

InsomniaPhase 3NCT00857220

Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

A Phase 3 study testing eszopiclone in people with Insomnia and Attention Deficit Hyperactivity Disorder, run by Sumitomo Pharma America, Inc. at 89 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia. Read more about this study

Who is it for?
Ages 6 to 17 years
What is being tested?
eszopiclone
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
304 participants
Where
89 sitesUnited States
Study dates
May 2009to Oct 2011
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Subject is male or female 6 17 years of age, inclusive, at the time of consent.
  • Subject must have a diagnosis of ADHD as defined by DSM-IV criteria • The diagnosis for Rollover subjects will be taken from the Screening visit of Study 190 246. Treatment naïve subjects will have these assessments performed at the Screening visit.
  • Subject must have documented ADHD associated insomnia, defined as the subject or subject's parent/legal guardian having reported repeated difficulty with sleep initiation (sleep latency >30 minutes) or consolidation (wake time after sleep onset > 45 minutes),>despite adequate age appropriate time and opportunity for sleep.
  • Subject has either >30 minutes latency to persistent sleep (LPS) or >45 minutes wake time after sleep onset (WASO) demonstrated by PSG.
  • Subject or subject's parent/legal guardian should have reported daytime functional impairment as a result of sleep problems.
  • Subject or subject's parent/legal guardian should have reported attempted and failed behavioral interventions for sleep problems, including a regular bedtime and rise time.
Show all 11Show fewer
  • Subject's sleep disturbance must not be attributable to either the direct physiologic effect of a drug of abuse or misuse of a prescribed medication whether it is being used as intended or in an illicit manner.
  • Female subjects ≥8 years of age must have a negative serum pregnancy test at screening
  • Subject must be in good general health.
  • Subject must be able to swallow tablets.
  • If subjects are currently taking medication for ADHD, they must be on a stable dose and regimen for at least one month, and preferably for at least 3 months prior to the time of consent

Who cannot join

  • Subject with weight <10th percentile for age and gender
  • Subject has any clinically significant or unstable medical abnormality/illness
  • Subject has a documented history of Bipolar I or II Disorder, major depression, conduct disorder, generalized anxiety disorder (other than obsessive-compulsive disorder) or any history of psychosis, as determined by medical or psychiatric history or as determined by clinical interview using the MINI-Kid at Visit 1.
  • Subject has periodic limb movement >5 times per hour, as demonstrated on PSG.
  • Subject has sleep disordered breathing, as demonstrated on PSG.
  • Subject has another primary sleep disorder (or secondary sleep disorder that is causing clinical impairment or any other known or suspected medical or psychiatric condition that has affected or may affect sleep
Show all 15Show fewer
  • Subject has a history of circadian rhythm disorder or will travel across ≥3 time zones more than once during the study.
  • Subject has organic brain disease, or a history of febrile seizures.
  • Subject is, in the opinion of the investigator, at suicidal or homicidal risk.
  • Female subject who is pregnant, lactating or planning to become pregnant.
  • Subject is taking any psychotropic or disallowed medications,
  • Subject has a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions.
  • Subject has a history of allergic reaction or has a known or suspected sensitivity to racemic zopiclone, eszopiclone, or any substance that is contained in the formulation.
  • Subject has a history of alcohol or substance abuse within 3 months of study participation
  • Subject has participated in any investigational study within 30 days prior to study entry or is currently participating in another clinical trial, except Study 190 246.

Trial locations and contacts

89 sites in 1 country.

89 sites in 1 country

United States89 sites
  • Academy of Clinical Research

    Arlington, Texas, 76011

  • Sleep Disorders Center of Georgia

    Atlanta, Georgia, 30342

  • NorthCoast Clinical Trials, Inc.

    Beachwood, Ohio, 44122

  • Neurobehavioral Medicine Group

    Bloomfield Hills, Michigan, 48302

  • Neuro-Behavioral Clnical Research

    Canton, Ohio, 44718

  • AV Institute, Inc.

    Carson, California, 90746

  • MD

    Chevy Chase, Maryland, 20815

  • Delta Waves, Inc.

    Colorado Springs, Colorado, 80918

  • Clinical Innovations, Inc.

    Costa Mesa, California, 92626

  • Pillar Clinical Research, LLC

    Dallas, Texas, 75243

  • InSite Clinical Research

    DeSoto, Texas, 75115

  • Mountain West Clinical Trials

    Eagle, Idaho, 83616

  • Suburban Lung Associates, SC

    Elk Grove Village, Illinois, 60007

  • Cutting Edge Research of Enid

    Enid, Oklahoma, 72703

  • Precise Research Centers

    Flowood, Mississippi, 39232

  • Sarkis Clinical Trials

    Gainesville, Florida, 32607

  • Behavioral Research Specialists, LLC

    Glendale, California, 91204

  • Cyn3rgy Research

    Gresham, Oregon, 97030

  • MD Clinical

    Hallandale, Florida, 3309

  • ActivMed Practices and Research

    Haverhill, Massachusetts, 01830

  • Clinical Research Center of Nevada

    Henderson, Nevada, 89015

  • Amedica Research Institute, Inc.

    Hialeah, Florida, 33013

  • Claghorn-Lesem Research Clinic, Ltd.

    Houston, Texas, 77008

  • Allegiant Clinical Research

    Houston, Texas, 77024

  • MD

    Houston, Texas, 77042

  • Sun Valley Research Center

    Imperial, California, 92251

  • Davis Clinic

    Indianapolis, Indiana, 46260

  • Goldpoint Clinical Research, LLC

    Indianapolis, Indiana, 46260

  • Holston Medical Group

    Kingsport, Tennessee, 37660

  • Eastside Therapeutic Resource

    Kirkland, Washington, 98033

  • Lake Charles Clinical Trials

    Lake Charles, Louisiana, 70601

  • Center for Psychiatry and Behavioral Medicine, Inc.

    Las Vegas, Nevada, 89128

  • Behavioral Clinical Research Inc.

    Lauderhill, Florida, 33319

  • Behavioral Clinical Research, Inc.

    Lauderhill, Florida, 33319

  • Capstone Clinical Research

    Libertyville, Illinois, 601048

  • Premier Psychicatric Research Institute, LLC

    Lincoln, Nebraska, 68510

  • Midwest Children's Health Research Institute

    Lincoln, Nebraska, 68516

  • Clinical Study Centers, LLC

    Little Rock, Arkansas, 72205

  • Brownsboro Park Pediatrics

    Louisville, Kentucky, 40207

  • Pediatric Neurology and Epilepsy Center

    Loxahatchee Groves, Florida, 33470

  • Florida Clinical Research Center, LLC

    Maitland, Florida, 32751

  • Cleveland Sleep Research Center

    Middleburg Heights, Ohio, 44130

  • North Star Medical Research, LLC

    Middleburg Heights, Ohio, 44130

  • AMR Baber Research, Inc.

    Naperville, Illinois, 60563

  • Nassim, McMonigle, Mescia & Associates

    New Albany, Indiana, 47150

  • Louisiana Research Associates, Inc.

    New Orleans, Louisiana, 70114

  • Neurocare, Inc.

    Newton, Massachusetts, 02459

  • ActivMed Practices and Research

    North Andover, Massachusetts, 01845

  • Scientific Clinical Research Inc.

    North Miami, Florida, 33161

  • Excell Research, Inc.

    Oceanside, California, 92056

  • North County Clinical Research (NCCR)

    Oceanside, California, 92056

  • IPS Research Company

    Oklahoma City, Oklahoma, 73103

  • Pahl Pharmaceutical Professionals, LLC

    Oklahoma City, Oklahoma, 73112

  • SP Research

    Oklahoma City, Oklahoma, 73112

  • Cutting Edge Research Group

    Oklahoma City, Oklahoma, 73116

  • Eminence Research LLC

    Oklahoma City, Oklahoma, 73139

  • Pacific Clinical Research Medical Group

    Orange, California, 92868

  • SDS Clinical Trials, Inc.

    Orange, California, 92868

  • Medical Research Group of Central Florida

    Orange City, Florida, 32763

  • Aspen Clinical Research, LLC

    Orem, Utah, 84058

  • Florida Institute for Clinical Research, LLC

    Orlando, Florida, 32822

  • Psychiatric Associates

    Overland Park, Kansas, 66211

  • Pedia Research, LLC

    Owensboro, Kentucky, 42301

  • CRI Worldwide

    Philadelphia, Pennsylvania, 19139

  • DMI Research Inc.

    Pinellas Park, Florida, 33782

  • The Mech Center

    Plano, Texas, 75024

  • Oregon Center for Clinical Investigations, Inc.

    Portland, Oregon, 97210

  • Global Medical Institutes, LLC

    Princeton, New Jersey, 08540

  • Alliance Research Group

    Richmond, Virginia, 23230

  • Clinical Innovations, Inc.

    Riverside, California, 92506

  • Northwest Behavioral Research Center

    Roswell, Georgia, 30076

  • Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)

    Salem, Oregon, 97301

  • Road Runner Research

    San Antonio, Texas, 78258

  • Artemis Institute for Clinical Research

    San Diego, California, 92123

  • Clinical Innovations

    San Diego, California, 92128

  • Neuropsychiatric Research Center of Orange County

    Santa Ana, California, 92701

  • Apex Research Institute

    Santa Ana, California, 92705

  • Clinical Innovations, Inc.

    Santa Ana, California, 92705

  • Florida Sleep Institute

    Spring Hill, Florida, 34609

  • Clinical Nuerophysiology Services, PC

    Sterling Heights, Michigan, 48314

  • SomnoMedics, LLC

    Tampa, Florida, 33607

  • REM Medical Clinical Research

    Tucson, Arizona, 85712

  • Paradigm Research Professonals, LLP

    Tulsa, Oklahoma, 74103

  • Tulsa Clinical Research

    Tulsa, Oklahoma, 74104

  • Sleep and Behavior Medicine Institute

    Vernon Hills, Illinois, 60061

  • Brighton Research Group, LLC

    Virginia Beach, Virginia, 23452

  • Omega Medical Research

    Warwick, Rhode Island, 02886

  • Elite Clinical Trials, Inc.

    Wildomar, California, 92595

  • CRI Worldwide, LLC

    Willingboro, New Jersey, 08046

Other trials in United States

About this study

Official title: A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia

A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.

Read the detailed description

This is a multi center, open label, long term safety study in pediatric subjects 6 through 17 years of age, inclusive, with a diagnosis of ADHD associated insomnia. Subjects who complete Study 190 246 (Rollover subjects) and meet the study enrollment criteria will be allowed to participate in this long term safety study. Additionally, Treatment naïve subjects will be enrolled in this long term safety study in order to meet the overall subject enrollment objective of obtaining 100 subjects with 12 months of treatment. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Being tested
eszopiclone
Keywords
Hypnotic, Eszopiclone, Attention Deficit Hyperactivity Disorder, Insomnia, Children, Adolescent
Medical subject headings
Sleep Initiation and Maintenance Disorders, Attention Deficit Disorder with Hyperactivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • eszopicloneDrug

    One 2 mg tablet per day for 12 months

  • eszopicloneDrug

    one 3mg tablet per day for 12 months

Study groups in NCT00857220
Study groupRoleWhat they receive
2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs)ExperimentalNot described
Receives: Drug: eszopiclone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall Incidence of Adverse Events

    Measured: 12 Months (from the 1st dose to the end of study)

Secondary outcomes (13)
  1. Overall Incidence of Skin Reactions: Number of Events

    Measured: 12 Months (from the 1st dose to the end of study)

  2. Overall Incidence of Skin Reactions: Number of Participant Affected

    Measured: 12 Months (from the 1st dose to the end of study)

  3. Columbia-Suicide Severity Rating Scale (C-SSRS) Item Responses

    The C-SSRS is a physician-completed scale to assess any suicidal ideation and suicidal behavior. The C-SSRS contained questions about suicidal behavior and suicidal ideation. Subjects were placed into categories for suicidal behavior and for suicidal ideation based on their responses to various questions. Any suicidality was defined as suicidal behavior or suicidal ideation. The suicidal behavior categories were determined based on the response to the questions under suicidal behavior (Completed Suicide, Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior).The suicidal ideation categories were determined by examining the response to 5 questions under suicidal ideation (Wish to be Dead, Nonspecific Active Suicidal Thoughts, Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act, Active Suicidal Ideation with Some Intent to Act, without Specific Plan, Active Suicidal Ideation with Specific Plan and Intent).

    Measured: 12 Months

  4. Change From Baseline in Coding Copy Subtest A or B, or Digit Symbol Substitution Test (DSST)at Month 12

    These tests are standardized information processing tasks to assess recognition and recoding of sensory information. The subject was given 90 seconds to complete as many substitutions of symbols as possible according to a code provided on top of the sheet. The Coding Copy Subtest A was used for subjects 6 to 7 years of age, the Coding Copy Subtest B was used for subjects 8 to 16 years of age, and the DSST was used for subjects 17 years of age. The DSST consists of rows containing small blank squares, each paired with a randomly assigned numbers 1-9. Above the rows is a key that pairs each number with a symbol. The subject must fill in the blank spaces with the matching symbol that is in the key. For the Subcopy tests the subject simply copies the symbol above each empty square. Scaled scores are used to account for age differences among test takers. Scaled scores range from 1 to 19, and higher scores indicate higher cognitive function.

    Measured: Baseline and 12 Months (from the 1st dose to the end of study)

  5. Clinical Global Impression (CGI) Improvement Score as Assessed by Parent/Caregiver or Child at Month 12

    A 7-point scale was used for improvement with numeric values assigned to each of the responses: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), and very much worse (7).

    Measured: Baseline and 12 Months (from the 1st dose to the end of study)

  6. Change From Baseline at Month 12 in Subjective Sleep Latency (SL)

    Sleep latency is the amount of time it takes to fall asleep after the lights have been turned off.

    Measured: Baseline and 12 Months (from the 1st dose to the end of study)

  7. Change From Baseline in Child Behavior Checklist (CBCL)

    CBCL was completed by parents or guardians who saw the child in home-like settings. It includes several competence items, open-ended items for describing the child's illnesses, disabilities, concerns about the child, best things about the child, and several items to rate behavioral, emotional, and social problems. Responses are recorded on a Likert scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The checklist contains 120 questions. The standardized score is computed by determining the z-score by subtracting the mean for the subject's age group and gender from the raw score and then dividing this by the standard deviation for the subject's age group and gender. Next, multiply the zscore by 15 and then add 100. For activities scale, social scale, school scale, and total competence scale, higher values indicate higher competencies. For Internalizing problems, externalizing problems, and total problems, higher values indicate more problems.

    Measured: Baseline and 12 Months (from the 1st dose to the end of study)

  8. Change From Baseline in Pediatric Daytime Sleepiness Scale (PDSS)at Month 12

    The PDSS total score ranges from a low of 0 where the individual is endorsing each item at the lowest level of daytime sleepiness to a high of 32 where the individual is endorsing each item at the highest level of daytime sleepiness.

    Measured: Baseline and 12 Months (from the 1st dose to the end of study)

  9. Change From Baseline in Conners' Continuous Performance Test II (CCPT II)

    The CCPT-II is a computer-based 14-minute, visual-performance task. During an administration, respondents were required to press the space bar or click the mouse whenever any letter except the target letter appears on the screen. The speed at which the letters were presented varied during the administration. There were 6 blocks, with 3 sub-blocks, each containing 20 trials (letter presentations). The interstimulus intervals (ISIs) were 1, 2, and 4 seconds with a display time of 250 milliseconds. The order in which the different ISIs were presented varied between blocks. Conners' CCPT-II provides the following measures:% Omissions,% Commissions, Hit Reaction Time, Hit Reaction Time Standard Error,Variability of Standard Error, Detectability (d'), Response Style (beta), Perseverations, Hit Reaction Time Block Change (Vigilance Measure), Hit Standard Error Block Change (Vigilance Measure), Hit Reaction Time ISI change, and Hit Standard Error ISI Change, Confidence Index.

    Measured: Baseline and 12 Months (from the 1st dose to the end of study)

  10. Change From Baseline at Month 12 in Subjective Wake Time After Sleep Onset (WASO)

    The sleep questionnaire, a Sponsor produced questionnaire used in previous eszopiclone studies, asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of the subject's sleep over a predefined time period. WASO was assessed based on the responses to the sleep questionnaire.

    Measured: Baseline and 12 Months (from the 1st dose to the end of study)

  11. Change From Baseline at Month 12 in Subjective Number of Awakening After Sleep Onset (NAASO)

    The sleep questionnaire, a Sponsor produced questionnaire used in previous eszopiclone studies, asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of the subject's sleep over a predefined time period. NAASO was assessed based on the responses to the sleep questionnaire.

    Measured: Baseline and 12 Months (from the 1st dose to the end of study)

  12. Change From Baseline at Month 12 in Subjective Total Sleep Time (TST).

    The sleep questionnaire, a Sponsor produced questionnaire used in previous eszopiclone studies, asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of the subject's sleep over a predefined time period. TST was assessed based on the responses to the sleep questionnaire.

    Measured: Baseline and 12 Months (from the 1st dose to the end of study)

  13. Change From Baseline in Pediatric Quality of Life Scale

    The SF-10™ Health Survey for Children is a 10-item care-giver completed assessment designed to measure children's health-related quality of life. The scale asked questions about the child's physical wellness, feelings, behavior, and activities at school and with family and friends. The SF-10 physical and psychosocial summary measures were scored such that higher scores indicated more favorable functioning. The Physical Summary Score is computed by summing values for questions 1, 2a, 2b, 3 and 5 and standardizing scores by normalizing to a total possible score of 0-100 with higher scores representing more positive indications. The Psychosocial Summary Score is computed by summing questions 4, 6, 7, 8, and 9 and standardizing scores by normalizing to a total possible score of 0-100 with higher scores representing more positive indications.

    Measured: Baseline and 12 Months (from the 1st dose to the end of study)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Mar 2009 (estimated)
  2. Study startMay 2009
  3. Primary completionOct 2011
  4. Study completionOct 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
304 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00857220
Sponsor's protocol ID
190-247
Status last verified
Sep 2017
First submitted
4 Mar 2009
Last updated
26 Oct 2017
Data monitoring committee
Yes

Publications

  • Sangal RB, Blumer JL, Lankford DA, Grinnell TA, Huang H. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder. Pediatrics. 2014 Oct;134(4):e1095-103. doi: 10.1542/peds.2013-4221.

    PubMed 25266438

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing eszopiclone in people with Insomnia and Attention Deficit Hyperactivity Disorder, run by Sumitomo Pharma America, Inc. at 89 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 89 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 Jul 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall Incidence of Adverse Events (time frame: 12 Months (from the 1st dose to the end of study)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00857220, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in